Data Insights

Emavusertib hydrochloride by Curis for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Emavusertib hydrochloride is under clinical development by Curis and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Emavusertib Hydrochloride in Chronic Lymphocytic Leukemia (CLL)

Data Insights

Emavusertib hydrochloride by Curis for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval

Emavusertib hydrochloride is under clinical development by Curis and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Emavusertib Hydrochloride in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)

Data Insights

Emavusertib hydrochloride by Curis for Metastatic Melanoma: Likelihood of Approval

Emavusertib hydrochloride is under clinical development by Curis and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Emavusertib Hydrochloride in Metastatic Melanoma

Data Insights

Emavusertib hydrochloride by Curis for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval

Emavusertib hydrochloride is under clinical development by Curis and currently in Phase II for Chronic Myelomonocytic Leukemia (CMML). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Emavusertib Hydrochloride in Chronic Myelomonocytic Leukemia (CMML)

Data Insights

Emavusertib hydrochloride by Curis for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia): Likelihood of Approval

Emavusertib hydrochloride is under clinical development by Curis and currently in Phase II for Chronic Myelocytic Leukemia (CML, Chronic Myeloid...

Likelihood of Approval and Phase Transition Success Rate Model - Emavusertib Hydrochloride in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)

Data Insights

Emavusertib hydrochloride by Curis for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Emavusertib hydrochloride is under clinical development by Curis and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According...

Likelihood of Approval and Phase Transition Success Rate Model - Emavusertib Hydrochloride in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Emavusertib hydrochloride by Curis for Esophageal Cancer: Likelihood of Approval

Emavusertib hydrochloride is under clinical development by Curis and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Emavusertib Hydrochloride in Esophageal Cancer

Data Insights

Emavusertib hydrochloride by Curis for Gastric Cancer: Likelihood of Approval

Emavusertib hydrochloride is under clinical development by Curis and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Emavusertib Hydrochloride in Gastric Cancer